Antibacterial activity of hinokitiol against both antibiotic-resistant and -susceptible pathogenic bacteria that predominate in the oral cavity and upper airways.


Journal

Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 07 02 2019
revised: 17 04 2019
accepted: 06 05 2019
pubmed: 21 5 2019
medline: 23 7 2019
entrez: 21 5 2019
Statut: ppublish

Résumé

Hinokitiol, a component of the essential oil isolated from Cupressaceae, possesses antibacterial and antifungal activities and has been used in oral care products. In this study, the antibacterial activities of hinokitiol toward various oral, nasal and nasopharyngeal pathogenic bacteria, including Streptococcus mutans, Streptococcus sobrinus, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Prevotella intermedia, Fusobacterium nucleatum, methicillin-resistant and -susceptible Staphylococcus aureus, antibiotic-resistant and -susceptible Streptococcus pneumoniae, and Streptococcus pyogenes were examined. Growth of all these bacterial strains was significantly inhibited by hinokitiol, minimal inhibitory concentrations of hinokitiol against S. mutans, S. sobrinus, P. gingivalis, P. intermedia, A. actinomycetemcomitans, F. nucleatum, methicillin-resistant S. aureus, methicillin-susceptible S. aureus, antibiotic-resistant S. pneumoniae isolates, antibiotic-susceptible S. pneumoniae, and S. pyogenes being 0.3, 1.0, 1.0, 30, 0.5, 50, 50, 30, 0.3-1.0, 0.5, and 0.3 μg/mL, respectively. Additionally, with the exception of P. gingivalis, hinokitiol exerted bactericidal effects against all bacterial strains 1 hr after exposure. Hinokitiol did not display any significant cytotoxicity toward the human gingival epithelial cell line Ca9-22, pharyngeal epithelial cell line Detroit 562, human umbilical vein endothelial cells, or human gingival fibroblasts, with the exception of treatment with 500 μg/mL hinokitiol, which decreased numbers of viable Ca9-22 cells and gingival fibroblasts by 13% and 12%, respectively. These results suggest that hinokitiol exhibits antibacterial activity against a broad spectrum of pathogenic bacteria and has low cytotoxicity towards human epithelial cells.

Identifiants

pubmed: 31106894
doi: 10.1111/1348-0421.12688
doi:

Substances chimiques

Anti-Bacterial Agents 0
Monoterpenes 0
Tropolone 7L6DL16P1T
beta-thujaplicin U5335D6EBI

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

213-222

Subventions

Organisme : JSPS KAKENHI
ID : 17H04367
Organisme : JSPS KAKENHI
ID : 16K11439
Organisme : JSPS KAKENHI
ID : 18K19638
Organisme : JSPS KAKENHI
ID : 17K19747
Organisme : Kobayashi International Scholarship Foundation
Organisme : Kobayashi Pharmaceutical Co., Ltd

Informations de copyright

© 2019 The Societies and John Wiley & Sons Australia, Ltd.

Auteurs

Hisanori Domon (H)

Division of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Research Center for Advanced Oral Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Takumi Hiyoshi (T)

Division of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Tomoki Maekawa (T)

Division of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Research Center for Advanced Oral Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Daisuke Yonezawa (D)

Division of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Research Center for Advanced Oral Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Division of Oral Science for Health Promotion, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Hikaru Tamura (H)

Division of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Research Center for Advanced Oral Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Shigetada Kawabata (S)

Department of Oral and Molecular Microbiology, Osaka University, Graduate School of Dentistry, Osaka, Japan.

Katsunori Yanagihara (K)

Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Osamu Kimura (O)

Shiokaze Clinic, Niigata, Japan.

Eiji Kunitomo (E)

Central Research and Development Laboratory, Kobayashi Pharmaceutical, Osaka, Japan.

Yutaka Terao (Y)

Division of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Research Center for Advanced Oral Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH